Inbakicept

Identification

Generic Name
Inbakicept
DrugBank Accession Number
DB16479
Background

Not Available

Type
Biotech
Groups
Investigational
Synonyms
  • Inbakicept
External IDs
  • ALT-803
  • ALT803
  • N-803
  • WHO 1102

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Inbakicept is a human IL-15 superagonist with immunostimulatory properties. Though a promising anti-cancer biologic, the drug is also being investigated as an HIV cure. It has the ability to reactivate latent virus, and has the potential to enhance anti-viral immune repsonses in these chronic infections.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Darbepoetin alfaThe risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Inbakicept.
ErythropoietinThe risk or severity of Thrombosis can be increased when Erythropoietin is combined with Inbakicept.
Methoxy polyethylene glycol-epoetin betaThe risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Inbakicept.
PeginesatideThe risk or severity of Thrombosis can be increased when Peginesatide is combined with Inbakicept.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
QN4LI58PJ5
CAS number
2135939-52-3

References

General References
  1. Webb GM, Molden J, Busman-Sahay K, Abdulhaqq S, Wu HL, Weber WC, Bateman KB, Reed JS, Northrup M, Maier N, Tanaka S, Gao L, Davey B, Carpenter BL, Axthelm MK, Stanton JJ, Smedley J, Greene JM, Safrit JT, Estes JD, Skinner PJ, Sacha JB: The human IL-15 superagonist N-803 promotes migration of virus-specific CD8+ T and NK cells to B cell follicles but does not reverse latency in ART-suppressed, SHIV-infected macaques. PLoS Pathog. 2020 Mar 12;16(3):e1008339. doi: 10.1371/journal.ppat.1008339. eCollection 2020 Mar. [Article]
  2. McBrien JB, Mavigner M, Franchitti L, Smith SA, White E, Tharp GK, Walum H, Busman-Sahay K, Aguilera-Sandoval CR, Thayer WO, Spagnuolo RA, Kovarova M, Wahl A, Cervasi B, Margolis DM, Vanderford TH, Carnathan DG, Paiardini M, Lifson JD, Lee JH, Safrit JT, Bosinger SE, Estes JD, Derdeyn CA, Garcia JV, Kulpa DA, Chahroudi A, Silvestri G: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. 2020 Feb;578(7793):154-159. doi: 10.1038/s41586-020-1946-0. Epub 2020 Jan 22. [Article]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingTreatmentNon-Small Cell Lung Carcinoma (NSCLC)1
2Active Not RecruitingTreatmentCervical Cancers / Colorectal Carcinoma (CRC) / Hepatocellular Carcinoma / Malignant Melanoma of Skin / Malignant Neoplasm of Stomach / Microsatellite Instability / Mismatch Repair-deficient (dMMR) / Neuroendocrine Carcinoma of the Skin / Non-Small Cell Lung Carcinoma (NSCLC) / Renal Cell Adenocarcinoma / Small Cell Lung Cancer (SCLC) / Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) / Transitional Cell, Carcinoma1
2CompletedTreatmentAcute Myeloid Leukemia (AML)1
2Not Yet RecruitingTreatmentAdvanced HNSCC / Gastroesophageal Junction (GEJ) Cancers1
2Not Yet RecruitingTreatmentCarcinoma, Non-Small Cell / Non-Small Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentAcute Myeloid Leukemia (AML)1
2RecruitingTreatmentAcute Myeloid Leukemia (AML) / Myelodysplastic Syndromes (MDS)1
2RecruitingTreatmentColorectal Carcinoma (CRC) / Small Bowel Cancers1
2RecruitingTreatmentHuman Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
2RecruitingTreatmentMalignant Neoplasm of Pancreas1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created on January 21, 2021 01:47 / Updated on September 15, 2021 23:26